TY - JOUR
T1 - Rapid initiation of antiretroviral therapy in Turkey
T2 - a modeling study
AU - Yaylali, Emine
AU - Erdogan, Zikriye Melisa
AU - Calisir, Fethi
AU - Pullukcu, Husnu
AU - Yildirim, Figen
AU - Inan, Asuman
AU - Aydin, Ozlem Altuntas
AU - Tekin, Suda
AU - Sonmezer, Meliha Cagla
AU - Sahin, Toros
AU - Ozcagli, Tahsin Gokcem
AU - Ozelgun, Berna
N1 - Publisher Copyright:
Copyright © 2024 Yaylali, Erdogan, Calisir, Pullukcu, Yildirim, Inan, Aydin, Tekin, Sonmezer, Sahin, Ozcagli and Ozelgun.
PY - 2024
Y1 - 2024
N2 - Background: To effectively control the HIV epidemic and meet global targets, policymakers recommend the rapid initiation of antiretroviral therapy (ART). Our study aims to investigate the effect of rapid ART programs on individuals diagnosed with HIV, considering varying coverage and initiation days after diagnosis, and compare it to standard-of-care ART treatment in Turkey. Methods: We used a dynamic compartmental model to simulate the dynamics of HIV infection in Turkey. Rapid treatment, defined as initiation of ART within 7 days of diagnosis, was contrasted with standard-of-care treatment, which starts within 30 days of diagnosis. This study considered three coverage levels (10%, 50%, and 90%) and two rapid periods (7 and 14 days after diagnosis), comparing them to standard-of-care treatment in evaluating the number of HIV infections between 2020 and 2030. Results: Annual HIV incidence and prevalence for a 10-year period were obtained from model projections. In the absence of a rapid ART program, the model projected approximately 444,000 new HIV cases while the number of cases were reduced to 345,000 (22% reduction) with 90% of diagnosed cases included in the rapid ART program. Similarly, 10% and 50% rapid ART coverage has resulted in 3% and 13% reduction in HIV prevalence over a 10-year period. Conclusion: Rapid ART demonstrates the potential to mitigate the increasing HIV incidence in Turkey by reducing the number of infections. The benefit of the rapid ART program could be substantial when the coverage of the program reaches above a certain percentage of diagnosed population.
AB - Background: To effectively control the HIV epidemic and meet global targets, policymakers recommend the rapid initiation of antiretroviral therapy (ART). Our study aims to investigate the effect of rapid ART programs on individuals diagnosed with HIV, considering varying coverage and initiation days after diagnosis, and compare it to standard-of-care ART treatment in Turkey. Methods: We used a dynamic compartmental model to simulate the dynamics of HIV infection in Turkey. Rapid treatment, defined as initiation of ART within 7 days of diagnosis, was contrasted with standard-of-care treatment, which starts within 30 days of diagnosis. This study considered three coverage levels (10%, 50%, and 90%) and two rapid periods (7 and 14 days after diagnosis), comparing them to standard-of-care treatment in evaluating the number of HIV infections between 2020 and 2030. Results: Annual HIV incidence and prevalence for a 10-year period were obtained from model projections. In the absence of a rapid ART program, the model projected approximately 444,000 new HIV cases while the number of cases were reduced to 345,000 (22% reduction) with 90% of diagnosed cases included in the rapid ART program. Similarly, 10% and 50% rapid ART coverage has resulted in 3% and 13% reduction in HIV prevalence over a 10-year period. Conclusion: Rapid ART demonstrates the potential to mitigate the increasing HIV incidence in Turkey by reducing the number of infections. The benefit of the rapid ART program could be substantial when the coverage of the program reaches above a certain percentage of diagnosed population.
KW - HIV care-continuum
KW - HIV infections
KW - infectious disease modeling
KW - mathematical modeling
KW - rapid antiretroviral treatment
UR - http://www.scopus.com/inward/record.url?scp=85184485823&partnerID=8YFLogxK
U2 - 10.3389/fpubh.2024.1224449
DO - 10.3389/fpubh.2024.1224449
M3 - Article
AN - SCOPUS:85184485823
SN - 2296-2565
VL - 12
JO - Frontiers in Public Health
JF - Frontiers in Public Health
M1 - 1224449
ER -